Bio-Rad Laboratories (NYSE:BIO) Price Target Lowered to $270.00 at Wells Fargo & Company

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) had its target price lowered by research analysts at Wells Fargo & Company from $320.00 to $270.00 in a report released on Thursday,Benzinga reports. The firm currently has an "equal weight" rating on the medical research company's stock. Wells Fargo & Company's target price suggests a potential upside of 10.08% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $380.20.

Bio-Rad Laboratories Trading Up 3.5 %

NYSE BIO traded up $8.40 on Thursday, hitting $245.28. 215,056 shares of the company were exchanged, compared to its average volume of 318,258. Bio-Rad Laboratories has a twelve month low of $215.38 and a twelve month high of $387.99. The company's 50 day moving average price is $254.11 and its 200-day moving average price is $310.67. The firm has a market capitalization of $6.87 billion, a P/E ratio of -3.77 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Analysts predict that Bio-Rad Laboratories will post 10.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of large investors have recently bought and sold shares of the business. Metis Global Partners LLC lifted its position in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after buying an additional 30 shares during the last quarter. Signaturefd LLC lifted its holdings in Bio-Rad Laboratories by 13.2% in the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after purchasing an additional 31 shares during the last quarter. UMB Bank n.a. boosted its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the period. Thrivent Financial for Lutherans grew its holdings in Bio-Rad Laboratories by 0.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock valued at $1,488,000 after purchasing an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in shares of Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock valued at $296,000 after purchasing an additional 34 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.